Learning Objectives:

• To discuss the recent approval of lifileucel and how it will impact the treatment of patients with advanced, refractory melanoma
• To review the clinical management and guidelines for the use of lifileucel and IL-2 at the University of Chicago
• To review the research horizon for next generations of TIL therapies

Session date: 
03/11/2024 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Daniel Olson, MD